[go: up one dir, main page]

DK1441708T3 - Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme - Google Patents

Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme

Info

Publication number
DK1441708T3
DK1441708T3 DK02789421T DK02789421T DK1441708T3 DK 1441708 T3 DK1441708 T3 DK 1441708T3 DK 02789421 T DK02789421 T DK 02789421T DK 02789421 T DK02789421 T DK 02789421T DK 1441708 T3 DK1441708 T3 DK 1441708T3
Authority
DK
Denmark
Prior art keywords
methods
therapies
compositions
alcoholism
treatment
Prior art date
Application number
DK02789421T
Other languages
Danish (da)
English (en)
Inventor
Seth Lederman
Original Assignee
Krele Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krele Pharmaceuticals Llc filed Critical Krele Pharmaceuticals Llc
Application granted granted Critical
Publication of DK1441708T3 publication Critical patent/DK1441708T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Addiction (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
DK02789421T 2001-11-05 2002-11-04 Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme DK1441708T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33890101P 2001-11-05 2001-11-05
PCT/US2002/035376 WO2003039525A1 (fr) 2001-11-05 2002-11-04 Compositions et methodes permettant d'augmenter l'observance therapeutique au moyen d'inhibiteurs de l'aldehyde deshydrogenase et traitement de l'alcoolisme

Publications (1)

Publication Number Publication Date
DK1441708T3 true DK1441708T3 (da) 2009-07-06

Family

ID=23326616

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02789421T DK1441708T3 (da) 2001-11-05 2002-11-04 Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme

Country Status (10)

Country Link
US (3) US20030087814A1 (fr)
EP (1) EP1441708B1 (fr)
AT (1) ATE427745T1 (fr)
AU (1) AU2002354017B2 (fr)
CA (1) CA2463987C (fr)
DE (1) DE60231896D1 (fr)
DK (1) DK1441708T3 (fr)
NZ (1) NZ532583A (fr)
PT (1) PT1441708E (fr)
WO (1) WO2003039525A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1441708B1 (fr) 2001-11-05 2009-04-08 Krele Pharmaceuticals LLC Compositions et methodes permettant d'augmenter l'observance therapeutique au moyen d'inhibiteurs de l'aldehyde deshydrogenase et traitement de l'alcoolisme
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EA016820B1 (ru) * 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
CA2727021A1 (fr) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Procede de purification de la base de la rasagiline
WO2011062614A1 (fr) * 2009-11-20 2011-05-26 Tonix Pharmaceuticals, Inc. Méthodes et compositions destinées à traiter les symptômes associés au stress consécutif à un traumatisme au moyen de cyclobenzaprine
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
CA2809966C (fr) * 2010-09-01 2019-01-08 Tonix Pharmaceuticals, Inc. Traitement contre la cocainomanie
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
HRP20200055T1 (hr) 2013-03-15 2020-04-03 Tonix Pharma Holdings Limited Eutektičke formulacije ciklobenzaprin-klorovodika i manitola
JP6614724B2 (ja) 2014-09-18 2019-12-04 トニックス ファーマ ホールディングス リミテッド シクロベンザプリン塩酸塩の共融製剤
JP2021505629A (ja) 2017-12-11 2021-02-18 トニックス ファーマ ホールディングス リミテッド 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置
AU2021385440A1 (en) * 2020-11-30 2023-06-29 Sophrosyne Pharmaceuticals Limited Compounds and methods for treating alcohol use disorder

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2567814A (en) * 1948-03-26 1951-09-11 Ayerst Mckenna & Harrison Tetraethyl thiuram disulfide alcoholism treatment composition
US3155584A (en) * 1962-12-03 1964-11-03 Abbott Lab Compositions and method of inhibiting monoamine oxidase and treating hypertension
SE404186B (sv) * 1975-06-09 1978-09-25 Astra Laekemedel Ab Forfarande for framstellning av cyklopropanolderivat
US4678809A (en) * 1985-02-01 1987-07-07 Michael Phillips Injectable fomulations of disulfiram for the treatment of alcoholism
US4565689A (en) * 1985-04-12 1986-01-21 Wirth Maschinen-Und Bohrgerate-Fabrik Gmbh Method for treating the effects of alcohol
US4868218A (en) * 1987-08-18 1989-09-19 Buyske Donald A Method of treating depression
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
GB8807504D0 (en) 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
WO1992005787A1 (fr) * 1990-10-01 1992-04-16 Radecki Thomas E Therapie par medicaments pour alcooliques
HU209605B (en) 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
WO1992021333A2 (fr) * 1991-05-24 1992-12-10 Pharmavene, Inc. Traitement des symptomes de sevrage et de manque dus a des drogues au moyen d'inhibiteurs d'oxydase de monoamine de type b
EP0520325A1 (fr) 1991-06-28 1992-12-30 F.Hoffmann-La Roche & Co. Aktiengesellschaft Utilisation des inhibiteurs d'oxydase monoaminée dans la prévention et le traitement de l'abus d'alcohol et de drogues
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
EP0593807A1 (fr) 1992-10-22 1994-04-27 LTS Lohmann Therapie-Systeme GmbH & Co. KG Pansement transdermique pour l'administration de principes actifs pharmaceutiques volatiles alcalins et procédé pour sa préparation
US5242950A (en) * 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
DE4428444A1 (de) * 1994-08-11 1996-02-15 Dresden Arzneimittel Verwendung von Selegilin zur Behandlung von epileptischen Erkrankungen
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
BR9501972A (pt) * 1995-05-09 1997-08-26 Tostes Luiz Roberto Mallat Composição farmacêutica metodo para tratamento de dependência ou abuso de álcool e método para tratamento de distúrbios psiquiátricos geneticamente relacionados ao alcoolismo
CN1116870C (zh) * 1996-03-15 2003-08-06 萨默塞特药品有限公司 司立吉林在制备用于预防或治疗外周神经病的药物中的应用
DE69614888D1 (de) * 1996-06-28 2001-10-04 Dallet Etienne Romeuf Sauze Au Durch muskelkraft angebtriebenen fahrzeug, insbesondere fahrrad
US6255497B1 (en) * 1997-04-29 2001-07-03 The Endowment For Research In Human Biology, Inc. Method for the inhibition of ALDH-I useful in the treatment of alcohol dependence or alcohol abuse
EP1043980A2 (fr) 1997-10-28 2000-10-18 Schering Corporation Procede de reduction de l'appetence chez les mammiferes
EP1077697B1 (fr) * 1998-05-12 2006-07-19 The Endowment For Research In Human Biology, Inc. Procedes et methodes de criblage utiles pour traiter la dependance a l'alcool ou l'abus d'alcool
FR2788982B1 (fr) 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
EP1441708B1 (fr) 2001-11-05 2009-04-08 Krele Pharmaceuticals LLC Compositions et methodes permettant d'augmenter l'observance therapeutique au moyen d'inhibiteurs de l'aldehyde deshydrogenase et traitement de l'alcoolisme

Also Published As

Publication number Publication date
US8481599B2 (en) 2013-07-09
EP1441708A1 (fr) 2004-08-04
DE60231896D1 (de) 2009-05-20
US8093300B2 (en) 2012-01-10
US20090005441A1 (en) 2009-01-01
WO2003039525A1 (fr) 2003-05-15
CA2463987C (fr) 2011-03-08
EP1441708A4 (fr) 2007-05-23
ATE427745T1 (de) 2009-04-15
EP1441708B1 (fr) 2009-04-08
US20120101154A1 (en) 2012-04-26
NZ532583A (en) 2006-12-22
AU2002354017B2 (en) 2007-08-16
CA2463987A1 (fr) 2003-05-15
PT1441708E (pt) 2009-06-18
US20030087814A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
WO2000040235A3 (fr) Traitement de l'asthme a l'aide d'inhibiteurs de mek
MXPA04004170A (es) Tratamiento del sindrome de resitencia a la insulina y diabetes de tipo 2 con inhibidores de pde9.
NO20034549L (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
MY138732A (en) Conjugated complement cascade inhibitors
IL158559A0 (en) Acne treatment
DK1441708T3 (da) Sammensætninger og fremgangsmåder til forögelse af föjelighed med terapier ved anvendelse af aldehyddehydrogenase-inhibitorer og behandling af alkoholisme
NO20056073L (no) Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS)
MXPA05008106A (es) Inhibidores del virus de la hepatitis c, composiciones y tratamientos que los emplean.
DK1957061T3 (da) Kombination omfattende mindst én aminosyre og en PKR-inhibitor til anvendelse i behandlingen af muskelsvind
WO2005000213A8 (fr) Methode permettant de traiter des maladies a l'aide d'agent d'inhibition hsp90 combines a des inhibiteurs d'enzymes
NO20060416L (no) Ny anvendelse I
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
MXPA05010476A (es) Composiciones de inhibidores selectivos de ciclooxigenasa-2 y agonistas de 5-hidroxitripamina1b/1d para el tratamiento y prevencion de migrana.
TW200505829A (en) Protease inhibitors for coronaviruses and sars-cov and the use thereof
WO2003024386A8 (fr) Utilisation d'inhibiteurs c-kit puissants, selectifs et non toxiques pour le traitement de la cystopathie interstitielle sous-muqueuse
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
DE60116642D1 (de) Verbindungen mit cytochrom p450ra1 hemmenden aktivität
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
WO2006029823A3 (fr) Procede de traitement de surfaces metalliques au moyen de formulations a base d'acide methanesulfonique a faible teneur en eau
WO2004098505A3 (fr) Attenuation des lesions ischemiques/de reperfusion
SE0301883D0 (sv) New use II
DK1865990T3 (da) Fremgangsmåde til behandling af type 2 diabetes
WO2006096769A3 (fr) Utilisation d'inhibiteurs de l'alpha-glucosidase pour traiter les infections par l'alphavirus
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors